查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1487536

急性间歇性卟啉症市场 - 全球产业分析、规模、份额、成长、趋势和预测，2024-2034 年

Acute Intermittent Porphyria Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 140 Pages | 商品交期: 2-10个工作天内

价格

急性间歇性卟啉症市场 - 报告范围

TMR 关于全球急性间歇性卟啉症市场的报告研究了过去以及当前的成长趋势和机会，以获得2024 年至2034 年预测期内市场指标的宝贵见解。的收入2018-2034年期间的市场，考虑2024年为基准年，2034年为预测年。报告也提供了2024年至2034年全球急性间歇性卟啉症市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解急性间歇性卟啉症市场。

市场概况
2023年市场价值 460万美元
2034 年市场价值 710 万美元
复合年增长率 3.9%

该报告深入研究了全球急性间歇性卟啉症市场的竞争格局。全球急性间歇性卟啉症市场的主要参与者已被确定，并且每位参与者都已根据各种属性进行了分析。本公司概述、财务状况、最新发展和 SWOT 是本报告中介绍的全球急性间歇性卟啉症市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：透过诊断

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依诊断，2020-2034
    • 验血
    • 尿液检查
    • 脱氧核糖核酸测试
    • 血清检测
  • 市场吸引力分析：透过诊断

第 7 章：全球市场分析与预测：按处理方式

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依处理方式，2020-2034
    • 促性腺激素释放激素类似物
    • 预防性血红素输注
  • 市场吸引力分析：按处理方式

第 8 章：全球市场分析与预测：按最终用户

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2020-2034
    • 医院
    • 诊所
    • 研究中心
  • 市场吸引力分析：按最终用户

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第 15 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Alnylam Pharmaceuticals, Inc.
    • Clinuvel Pharmaceuticals Ltd.
    • BioMarin Pharmaceutical Inc.
    • Recordati
    • Quest Diagnostics
    • Invitae Corp.
    • Laboratory Corporation of America Holdings (Labcorp)
    • ARUP Laboratories
Product Code: TMRGL42014

Acute Intermittent Porphyria Market - Scope of Report

TMR's report on the global acute intermittent porphyria market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global acute intermittent porphyria market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute intermittent porphyria market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute intermittent porphyria market.

Market Snapshot
Market Value in 2023US$ 4.6 Mn
Market Value in 2034US$ 7.1 Mn
CAGR3.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute intermittent porphyria market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global acute intermittent porphyria market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute intermittent porphyria market.

The report delves into the competitive landscape of the global acute intermittent porphyria market. Key players operating in the global acute intermittent porphyria market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global acute intermittent porphyria market profiled in this report.

Key Questions Answered in Global acute intermittent porphyria Market Report:

  • What is the sales/revenue generated by acute intermittent porphyria across all regions during the forecast period?
  • What are the opportunities in the global acute intermittent porphyria market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Acute Intermittent Porphyria Market - Research Objectives and Research Approach

The comprehensive report on the global acute intermittent porphyria market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global acute intermittent porphyria market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global acute intermittent porphyria market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Acute Intermittent Porphyria Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Acute Intermittent Porphyria Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Diagnosis

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Diagnosis, 2020-2034
    • 6.3.1. Blood Test
    • 6.3.2. Urine Test
    • 6.3.3. DNA Test
    • 6.3.4. Serum Test
  • 6.4. Market Attractiveness Analysis, by Diagnosis

7. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Treatment

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Treatment, 2020-2034
    • 7.3.1. Gonadotropin-Releasing Hormone Analogues
    • 7.3.2. Prophylactic Hematin Infusions
  • 7.4. Market Attractiveness Analysis, by Treatment

8. Global Acute Intermittent Porphyria Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020-2034
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Research Centers
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Acute Intermittent Porphyria Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Acute Intermittent Porphyria Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Diagnosis, 2020-2034
    • 10.3.1. Blood Test
    • 10.3.2. Urine Test
    • 10.3.3. DNA Test
    • 10.3.4. Serum Test
  • 10.4. Market Value Forecast, by Treatment, 2020-2034
    • 10.4.1. Gonadotropin-Releasing Hormone Analogues
    • 10.4.2. Prophylactic Hematin Infusions
  • 10.5. Market Value Forecast, by End-user, 2020-2034
    • 10.5.1. Hospitals
    • 10.5.2. Clinics
    • 10.5.3. Research Centers
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Diagnosis
    • 10.7.2. By Treatment
    • 10.7.3. By End-user
    • 10.7.4. By Country

11. Europe Acute Intermittent Porphyria Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Diagnosis, 2020-2034
    • 11.3.1. Blood Test
    • 11.3.2. Urine Test
    • 11.3.3. DNA Test
    • 11.3.4. Serum Test
  • 11.4. Market Value Forecast, by Treatment, 2020-2034
    • 11.4.1. Gonadotropin-Releasing Hormone Analogues
    • 11.4.2. Prophylactic Hematin Infusions
  • 11.5. Market Value Forecast, by End-user, 2020-2034
    • 11.5.1. Hospitals
    • 11.5.2. Clinics
    • 11.5.3. Research Centers
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Diagnosis
    • 11.7.2. By Treatment
    • 11.7.3. By End-user
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Acute Intermittent Porphyria Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Diagnosis, 2020-2034
    • 12.3.1. Blood Test
    • 12.3.2. Urine Test
    • 12.3.3. DNA Test
    • 12.3.4. Serum Test
  • 12.4. Market Value Forecast, by Treatment, 2020-2034
    • 12.4.1. Gonadotropin-Releasing Hormone Analogues
    • 12.4.2. Prophylactic Hematin Infusions
  • 12.5. Market Value Forecast, by End-user, 2020-2034
    • 12.5.1. Hospitals
    • 12.5.2. Clinics
    • 12.5.3. Research Centers
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Diagnosis
    • 12.7.2. By Treatment
    • 12.7.3. By End-user
    • 12.7.4. By Country/Sub-region

13. Latin America Acute Intermittent Porphyria Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Diagnosis, 2020-2034
    • 13.3.1. Blood Test
    • 13.3.2. Urine Test
    • 13.3.3. DNA Test
    • 13.3.4. Serum Test
  • 13.4. Market Value Forecast, by Treatment, 2020-2034
    • 13.4.1. Gonadotropin-Releasing Hormone Analogues
    • 13.4.2. Prophylactic Hematin Infusions
  • 13.5. Market Value Forecast, by End-user, 2020-2034
    • 13.5.1. Hospitals
    • 13.5.2. Clinics
    • 13.5.3. Research Centers
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Diagnosis
    • 13.7.2. By Treatment
    • 13.7.3. By End-user
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Acute Intermittent Porphyria Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Diagnosis, 2020-2034
    • 14.3.1. Blood Test
    • 14.3.2. Urine Test
    • 14.3.3. DNA Test
    • 14.3.4. Serum Test
  • 14.4. Market Value Forecast, by Treatment, 2020-2034
    • 14.4.1. Gonadotropin-Releasing Hormone Analogues
    • 14.4.2. Prophylactic Hematin Infusions
  • 14.5. Market Value Forecast, by End-user, 2020-2034
    • 14.5.1. Hospitals
    • 14.5.2. Clinics
    • 14.5.3. Research Centers
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Diagnosis
    • 14.7.2. By Treatment
    • 14.7.3. By End-user
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Alnylam Pharmaceuticals, Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Clinuvel Pharmaceuticals Ltd.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. BioMarin Pharmaceutical Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Recordati
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Quest Diagnostics
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Invitae Corp.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Laboratory Corporation of America Holdings (Labcorp)
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. ARUP Laboratories
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview

List of Tables

  • Table 01: Global Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
  • Table 02: Global Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
  • Table 03: Global Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 04: Global Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 05: North America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 06: North America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
  • Table 07: North America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
  • Table 08: North America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 09: Europe Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
  • Table 11: Europe Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
  • Table 12: Europe Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 13: Asia Pacific Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
  • Table 15: Asia Pacific Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
  • Table 16: Asia Pacific Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 17: Latin America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
  • Table 19: Latin America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
  • Table 20: Latin America Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 21: Middle East & Africa Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Diagnosis, 2020-2034
  • Table 23: Middle East & Africa Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by Treatment, 2020-2034
  • Table 24: Middle East & Africa Acute Intermittent Porphyria Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Acute Intermittent Porphyria Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Acute Intermittent Porphyria Market Revenue (US$ Mn), by Diagnosis, 2023
  • Figure 03: Global Acute Intermittent Porphyria Market Value Share, by Diagnosis, 2023
  • Figure 04: Global Acute Intermittent Porphyria Market Revenue (US$ Mn), by Treatment, 2023
  • Figure 05: Global Acute Intermittent Porphyria Market Value Share, by Treatment, 2023
  • Figure 06: Global Acute Intermittent Porphyria Market Revenue (US$ Mn), by End-user, 2023
  • Figure 07: Global Acute Intermittent Porphyria Market Value Share, by End-user, 2023
  • Figure 08: Global Acute Intermittent Porphyria Market Value Share, by Region, 2023
  • Figure 09: Global Acute Intermittent Porphyria Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 10: Global Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
  • Figure 11: Global Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 13: Global Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
  • Figure 14: Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 15: Global Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 16: Global Acute Intermittent Porphyria Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Acute Intermittent Porphyria Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Acute Intermittent Porphyria Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Acute Intermittent Porphyria Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
  • Figure 22: North America Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 23: North America Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 24: North America Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
  • Figure 26:North America Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 27: Europe Acute Intermittent Porphyria Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Acute Intermittent Porphyria Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Acute Intermittent Porphyria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
  • Figure 31: Europe Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 32: Europe Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 33: Europe Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
  • Figure 35: Europe Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 36: Asia Pacific Acute Intermittent Porphyria Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Acute Intermittent Porphyria Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Acute Intermittent Porphyria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
  • Figure 40: Asia Pacific Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 41: Asia Pacific Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 42: Asia Pacific Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
  • Figure 44: Asia Pacific Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 45: Latin America Acute Intermittent Porphyria Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Acute Intermittent Porphyria Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Acute Intermittent Porphyria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
  • Figure 49: Latin America Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 50: Latin America Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Latin America Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
  • Figure 53: Latin America Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 54: Middle East & Africa Acute Intermittent Porphyria Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Acute Intermittent Porphyria Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Acute Intermittent Porphyria Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Acute Intermittent Porphyria Market Value Share Analysis, by Diagnosis, 2023 and 2034
  • Figure 58: Middle East & Africa Acute Intermittent Porphyria Market Value Share Analysis, by Treatment, 2023 and 2034
  • Figure 59: Middle East & Africa Acute Intermittent Porphyria Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 60: Middle East & Africa Acute Intermittent Porphyria Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Acute Intermittent Porphyria Market Attractiveness Analysis, by Treatment, 2024-2034
  • Figure 62: Middle East & Africa Acute Intermittent Porphyria Market Attractiveness Analysis, by End-user, 2024-2034